Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
|
|
|
- Juliana Lynch
- 6 years ago
- Views:
Transcription
1 Page 1 of 6 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ ] % $ bil 2.9 mil 3.2 mil Stock Price XNYS:LLY: % 2018 Morningstar s Take Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its longterm growth. Following... Key Stats Stock Ind Avg Price/Earnings TTM Price/Book Price/Sales TTM Rev Growth (3 Yr Avg) Net Income Growth (3 Yr Avg) Operating Margin % TTM Net Margin % TTM ROA TTM ROE TTM Debt/Equity Financials Fair Value Estimate $ Consider Buying $ Consider Selling $ Fair Value Uncertainty Medium Economic Moat Wide Stewardship Standard Growth C Profitability V Morningstar Credit Rating Relative to Industry - Avg + Annual Quarterly Income Statement Revenue 21,222 19,959 19,616 5,658 5,192 Operating Income 3,841 3,057 3,329 1, Net Income 2,738 2,408 2, Earnings Per Share Shares Outstanding 1,062 1,066 1,074 1,056 1,061 Balance Sheet Current Assets 15,101 12,574 12,180 17,428 13,386 Non Current Assets 23,704 22,995 24,998 25,582 24,204 Total Assets 38,806 35,569 37,178 43,010 37,590 Current Liabilities 10,987 8,230 11,208 12,666 8,273 Total Liabilities 24,798 20,998 21,805 28,120 22,001 Stockholders' Equity 14,008 14,571 15,373 14,890 15,589 Dividends Declared Date 11/12/2017 Ex-Dividend Date 14/02/2018 Latest Indicated Dividend Amount 0.56 Projected Yield 2.60 % Recent Dividends & Type Amount Splits 11/14/2017 Cash Dividends /11/2017 Cash Dividends /11/2017 Cash Dividends /13/2017 Cash Dividends Competitors Name Price % Chg TTM Sales $ mil Eli Lilly and Co $ ] 22,471 Johnson & Johnson $ ] 74,361 Roche Holding AG ADR $ ] 53,210 Roche Holding AG Dividend Right Cert. $ [ 53,210 Roche Holding AG $ [ 53,210 Pfizer Inc $ ] 52,471 Recommendations Current 4.0 Total Analysts: Buy Hold Sell Ownership Fund Owners Star Rating % Shares Held % Total Assets Beutel Goodman QQQQQ American Equity Class D BMO US Equity A QQQ HEXAVEST US QQQ HEXAVEST WORLD QQQQ Beutel Goodman BalancedQQQQQ Class D Insiders % Change TTM % Shares Outstanding John C Lechleiter -299, Jan M. Lundberg 32, Jeffrey N. Simmons 7, Enrique A. Conterno Maria A. Crowe 31, Cash Flow Cash From Operations 4,851 2,773 4,367 1,881 1,659 Capital Expenditures -1,037-1,066-1,
2 Morningstar Analyst Rating. Page 2 of 6 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ ] % $ bil 2.9 mil 3.2 mil Financials Annual Quarterly Free Cash Flow 3,814 1,707 2,896 1,433 1,432 In millions except "EPS". Currency in USD.
3 Page 3 of 6 Industry Classification NAICS Pharmaceutical Preparation Manufacturing (325412) SIC Pharmaceutical and Medicine Industry (3741);Pharmaceutical Preparations (2834) ISIC Manufacture of Pharmaceuticals, Medicinal Chemical and Botanical Products (2100) Operation Details Fiscal Year Ends CIK Year Established Employees (31/12/2016) Full Time Part Time Auditor (31/12/2016) Ernst & Young LLP Legal Advisor (01/03/2013) Covington & Burling LLP Key Executives Jan M. Lundberg/Executive Vice President, Science and Technology and President, Lilly Research Laboratories; Jeffrey N. Simmons/Senior Vice President and President, Elanco Animal Health; Enrique A. Conterno/Senior Vice President and President, Lilly USA; Maria A. Crowe/President, Manufacturing Operations; Barton R. Peterson/Senior Vice President, Corporate Affairs and Communications; David A. Ricks/Director, President and Chief Executive Officer; Stephen Fry/Senior Vice President, Human Resources and Diversity; Fionnuala M. Walsh/Senior Vice President, Global Quality; Michael J. Harrington/Senior Vice President and General Counsel; Alfonso G. Zulueta/Senior Vice President and President, Lilly International; Susan Mahony/Senior Vice President and President, Lilly Oncology; Melissa S. Barnes/Senior Vice President, Enterprise Risk Management and Chief Ethics and Compliance Officer; Donald A. Zakrowski/Vice President, Finance and Chief Accounting Officer Company Profile Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products. 30-day Avg Volume Market Cap Net Income Sales Sector Industry Stock Style Direct Investment Dividend Reinvestment 3.3Mil 95.3Bil 2.2Bil 22.5Bil Healthcare Drug Manufacturers - Major 4 Large Core Yes Yes
4 Page 4 of 6 Industry Peers Morningstar Rating Market Cap $Mil Net Income $Mil P/S P/B P/E Dividend Yield% 5 Yr Rev CAGR% Med Oper. Margin% Interest Coverage Eli Lilly and Co QQQ 95,321 2, Johnson & Johnson (USD) QQ 380,706 15, Roche Holding AG (USD,CHF) QQQQQ 221,125 9, Roche Holding AG (USD,CHF) 221,125 9, Roche Holding AG (USD,CHF) 221,125 9, Pfizer Inc (USD) QQQ 219,711 9, Novartis AG (USD) QQQ 202,112 6, Novartis AG (USD) 202,112 6, AbbVie Inc (USD) QQ 161,415 6, Merck & Co Inc (USD) QQQQ 155,265 2, Sanofi SA (USD,EUR) QQQQ 110,865 9, Sanofi SA (USD,EUR) 110,865 9, Bayer AG (USD,EUR) 104,048 7, Bayer AG (USD,EUR) QQQQ 104,048 7, Bristol-Myers Squibb Company (USD) QQQ 101,295 4, GlaxoSmithKline PLC (USD,GBP) QQQQ 88,761 2, GlaxoSmithKline PLC (USD,GBP) 88,761 2, AstraZeneca PLC (USD) QQ 88,704 3, AstraZeneca PLC (USD) 88,704 3, AstraZeneca PLC (USD) 88,446 3, Chugai Pharmaceutical Co Ltd (USD,JPY) 28,859 67, Chugai Pharmaceutical Co Ltd (USD,JPY) 28,084 67, Astellas Pharma Inc (USD,JPY) 25, , Astellas Pharma Inc (USD,JPY) 25, , Otsuka Holdings Co Ltd (USD,JPY) 24,389 57, Otsuka Holdings Co Ltd (USD,JPY) 24,389 57, Daiichi Sankyo Co Ltd (USD,JPY) 18,201 38, Daiichi Sankyo Co Ltd (USD,JPY) 18,201 38, CSPC Pharmaceutical Group Ltd (USD,HKD) 14,055 2, Kyowa Hakko Kirin Co Ltd (USD,JPY) 11,170 21, Ono Pharmaceutical Co Ltd (USD,JPY) 11,161 53, Ono Pharmaceutical Co Ltd (USD,JPY) 11,161 53, Recordati (USD,EUR) 8, Santen Pharmaceutical Co Ltd (USD,JPY) 6,519 25, Santen Pharmaceutical Co Ltd (USD,JPY) 6,519 25, PT Kalbe Farma Tbk (USD,IDR) 6,146 2,376, PT Kalbe Farma Tbk (USD,IDR) 6,146 2,376, Alfresa Holdings Corp (USD,JPY) 5,262 31, Hutchison China Meditech Ltd (USD) 4, Hutchison China Meditech Ltd (USD) 4, GW Pharmaceuticals PLC (USD,GBP) 3, GW Pharmaceuticals PLC (USD,GBP) 3, Dechra Pharmaceuticals PLC (USD,GBP) 2, Cosmo Pharmaceuticals NV (USD,EUR) 2, Aerie Pharmaceuticals Inc (USD) 2, Haw Par Corp Ltd (USD,SGD) 1, Haw Par Corp Ltd (USD,SGD) 1, Tong Ren Tang Technologies Co Ltd (USD,CNY) 1, Boiron SA (USD,EUR) 1, TherapeuticsMD Inc (USD) 1, D/E
5 Page 5 of 6 Industry Peers United Laboratories International Holdings Ltd 1, (USD,CNY) Virbac SA (USD,EUR) 1, Zogenix Inc (USD) 1, Vectura Group PLC (USD,GBP) 1, Retrophin Inc (USD) Vetoquinol SA (USD,EUR) Nichi-Iko Pharmaceutical Co Ltd (USD,JPY) 867 5, Mayne Pharma Group Ltd (USD,AUD) Torii Pharmaceutical Co Ltd (USD,JPY) 773 3, Tempo Scan Pacific Tbk (USD,IDR) , Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (USD,CNY) Eco Animal Health Group PLC (USD,GBP) AB Science (USD,EUR) Rockwell Medical Inc (USD) Allergy Therapeutics PLC (USD,GBP) Daiken Medical Co Ltd (USD,JPY) 205 1, Opthea Ltd (USD,AUD) Opthea Ltd (USD,AUD) SymBio Pharmaceuticals Ltd (USD,JPY) 102-3, ,357.2 Alimera Sciences Inc (USD) PhotoCure ASA (USD,NOK) Pharmaxis Ltd (USD,AUD) Futura Medical PLC (USD,GBP) ,274.6 Moberg Pharma AB (USD,SEK) Nanoviricides Inc (USD) Oasmia Pharmaceutical AB (USD,SEK) , Tonix Pharmaceuticals Holding Corp (USD) ProPhase Labs Inc (USD) Avivagen Inc (USD,CAD) , China Pharma Holding Inc (USD) NeuroVive Pharmaceutical AB (USD,SEK) , , Innovus Pharmaceuticals Inc (USD) Alliqua BioMedical Inc (USD) Immune Pharmaceuticals Inc (USD) , Sunwin Stevia International Inc (USD) Biostar Pharmaceuticals Inc (USD) Aoxing Pharmaceutical Co Inc (USD) Antisense Therapeutics Ltd (USD,AUD) Integrated Biopharma Inc (USD) Enzyme Bio Systems (USD) ,320.8 Echo Therapeutics Inc (USD) , ,445.6 Tongli Pharmaceuticals (USA) Inc (USD) Enzymes American Holding Corp Cell Tech International Inc (USD) Skystar Bio-Pharmaceutical Co (USD) Canopus Biopharma Inc JinZangHuang Tibet Pharmaceuticals Inc (USD) GFR Pharmaceuticals Inc (USD) Global Pharmatech Inc (USD) Somatic Systems Inc Emerging World Pharma Inc InterNatural Pharmaceuticals Inc
6 Page 6 of 6 Industry Peers Neurogenesis Inc Pharmaconnect Inc Innovative Holdings Alliance Inc Endocan Corp (USD) Genex Pharmaceutical Inc (USD) Laxai Pharma Ltd (USD) Winston Pharmaceuticals Inc (USD) Nouveau Life Pharmaceuticals Inc (USD) Nutrastar International Inc (USD) AtheroNova Inc (USD) Biotie Therapies Corp (USD,EUR) Hubei Minkang Pharmaceutical Ltd (USD) China Health Resource Inc (USD) Kun Run Biotechnology Inc (USD) Alfresa Holdings Corp (USD,JPY) 31, Merck Tbk (USD,IDR) 157, Bohai Pharmaceuticals Group Inc (USD) Star Nutrition Inc Shandong Luoxin Pharmaceutical Group Stock Co Ltd ,394.3 (USD,CNY) Adia Nutrition Inc Shandong Luoxin Pharmaceutical Group Stock Co Ltd (USD,CNY) ,394.3 Cipla Ltd (USD,INR) 11, Dawnrays Pharmaceutical (Holdings) Ltd (USD,CNY) ,123.9 Artec Inc NV Global Green Inc (USD) Beximco Pharmaceuticals Ltd (USD,BDT) 2, Torrent Pharmaceuticals Ltd (USD,INR) 8, Piramal Enterprises Ltd (USD,INR) 14, GlaxoSmithKline Pharmaceuticals Ltd (USD,INR) 3, , Il Yang Pharmaceutical Co Ltd (USD,KRW) 4, Pierrel SpA (USD,EUR) Dong Xin Bio-Tech Pharmaceutical Inc Xi An 38 Fule Health & Advisory Co Ltd Whanin Pharm Co Ltd (USD,KRW) 22, Shandong Xinhua Pharmaceutical Co Ltd (USD,CNY) Mayne Pharma Group Ltd (USD,AUD) Kyowa Hakko Kirin Co Ltd (USD,JPY) 21, Industry Average 37,152 52, , ,
Skystar Bio-Pharmaceutical Co SKBI
Morningstar Analyst Rating Page 1 of 6 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 0.00 [0.00 0.00 % $ 0.00 0.00-0.00 0.00-0.10
Skystar Bio-Pharmaceutical Co SKBI
Morningstar Analyst Rating Page 1 of 6 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 0.01 [0.00 0.00 % $ 0.01 0.01-0.01 0.00-0.20
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 7 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 108.67 [-0.90-0.82 % $ 109.49 108.45-109.68
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Duke COI Reporting is based on the previous year and anticipated relationships for the coming year. Please report current and anticipated information for the
(3) Educational Activities or Lectures for this Company Generates Revenue for Duke $5K $25K >$25K
DCRI Commercial relationships Tracking Form Year: 2018 Name: Adrian Hernandez, M.D. Title: Vice Dean, Clinical, School of Medicine Address: 200 Trent Dr., Durham NC 27710 Please complete the applicable
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM COI Reporting is based on the previous year and anticipated relationships for the coming year. Please report current and anticipated information for the calendar
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION)
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION) Feedback from 93 Eastern-European patient groups PUBLISHED JULY 2016 CONTENTS ABOUT THIS REPORT Page 1 WHAT DID
GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS
GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS PHM006K March 2016 Himani Singhi Wadhwa Project Analyst ISBN: 1-62296-254-0 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
Method of Declaration. Hospitality/Interest/Sponsorship
Hospitality/Interest/Sponsorship Date Received Method of Declaration Abbott Laboratories Limited 23/03/12 Sponsorship Abbott Laboratories Limited 28/05/12 Sponsorship Abbott Laboratories Limited 23/03/12
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Duke COI Reporting is based on the previous year and anticipated relationships for the coming year. Please report current and anticipated information for the
Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Year(s): 2015 Name: Patrick Pun, MD Title: Asasistant Professor of Medicine Address: DCRI Please complete the applicable rows in the following table. Monetary
Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Duke COI Reporting is based on the previous year and anticipated relationships for the coming year. Please report current and anticipated information for the
Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing
Gilead Sciences. Very interesting in all areas. COMPANY Gilead Sciences Inc. INDUSTRY Biotechnology TYPE Public Company TICKER NasdaqGS:GILD
Simply Wall St provides a completely new visual way to invest in the stock market. To see other infographic reports like this one for Apple check out simplywall.st. Very interesting in all areas. COMPANY
Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Year(s): 2016 Name: Shelby D. Reed, PhD Title: Professor Address: PO Box 17969, Durham, NC 27715 Please complete the applicable rows in the following table.
Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector Publishing Intelligence Limited
Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D
Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer Eli Lilly and Company Washington Biotechnology &
State of Licensing 2011 Update
State of Licensing 2011 Update Moderators/Speakers Hemmie Chang, Chair, Licensing & Strategic Alliance Practice Group, Foley Hoag LLP Ranya Dajani, Executive Director, Strategic Transactions Group, Bristol-
Associate Director. Biomarker Operations Lead. Business Development & Strategic Alliances. Business Development Executive
Job Title Alliance Lead Analytics Specialist Associate Director Associate Director Diagnostics Partnering Associate Director Business Development Associate Director Application Architecture Associate Manager
KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018
KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018 KKR Today Private Markets Public Markets Capital Markets Principal Activities $104bn AUM $91bn AUM Global Franchise $19bn
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM COI Reporting is based on the previous year and anticipated relationships for the coming year. Please report information for the calendar year 2014 and anticipated
Management to Host Conference Call at 8:30 a.m. ET today
Aclaris Therapeutics Reports Second Quarter 2016 Financial Results August 11, 2016 7:01 AM ET Management to Host Conference Call at 8:30 a.m. ET today MALVERN, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:ACRS),
The 2011 EU industrial R&D investment SCOREBOARD
1 The 2011 EU industrial R&D investment SCOREBOARD Joint Research Centre European Commission Héctor Hernández Alex Tuebke Fernando Hervás 1. Background 2 Understanding the dynamics of industrial R&D at
PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update
PwC Deals Q3 16 Update Executive summary Global Pharma and Life Sciences (PLS) deal activity declined both in volume and value this quarter compared to the prior quarter and Q3 15. The considerable decrease
Annual Press Conference Financial year 2017
Annual Press Conference 2018 Financial year 2017 Financial year Hubertus von Baumbach Chairman of the Board of Managing Directors 2017 Highly successful financial year 2017 Major success with human pharmaceuticals
Early Valuation. Company Portfolio
Early Valuation Company Portfolio The current strategy Idea PoC Regulatory Clinical Development Basic Science / Experts Operations Marketing / KOL Commercial Health Innovation Technology Transfer 1 I d
Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and market
NOT FOR DISTRIBUTION IN THE USA,CANADA, JAPAN OR AUSTRALIA
Press release Baar, 28 January 2008 Attractive portfolio of investments in biotech and medical technology to be opened to the public HBM BioVentures announces further information of its planned IPO on
Investor Presentation. November 2018
Investor Presentation November 2018 KKR Today Private Markets Public Markets Capital Markets Principal Activities $104bn AUM $91bn AUM Global Franchise $19bn of Assets $81bn Private Equity, Growth Equity
Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through
Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through 2015 www.pharmsource.com 1 Presenters Jim Miller President and Founder, PharmSource Saul Richmond, PhD Director of Market Intelligence,
4 th Quarter Earnings Conference Call
4 th Quarter Earnings Conference Call KKR & Co. Inc. Investor Update February 1, 2019 Key Metrics Assets Under Management Management Fees ($ in billions) ($ in millions) $195 $1,069 $168 $905 $100 $107
KKR & Co. L.P. Morgan Stanley Financials Conference: June 13, 2018
KKR & Co. L.P. Morgan Stanley Financials Conference: June 13, 2018 ($ in trillions) KKR Growth in Alternative Asset Market Share KKR AUM +20% CAGR +21% CAGR Alternative AUM +12% CAGR $190 (1) ($ in billions)
HBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio
HBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio SECA conference Zurich, 3 July 2013 Dr. Andreas Wicki, CEO HBM at a Glance SIX-listed investment company
Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio
Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting Tokyo, Japan March 16, 2010 Astellas Pharma Inc. (TSE: 4503) today notified
Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business
Reference List Cha, Myoung., and Theresa Lorriman. February Why Pharma megamergers work. McKinsey&Company Our insights. Ward, Andrew.
Reference List Cha, Myoung., and Theresa Lorriman. February 2014. Why Pharma megamergers work. McKinsey&Company Our insights. Ward, Andrew. September 24, 2015. Pharmaceuticals: Value over Volume. Financial
Voting Procedure (con t)
2 Voting Procedure 1 ( 5 ) One share shall have one vote. A shareholder may cast his/her vote to either approve, disapprove or abstain from voting. Except for Agenda Item 5 regarding election of directors,
Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile
Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business
Born Ph.D. from Karolinska Institutet in Stockholm. Board member since 2016.
Board of Directors Håkan Björklund Chairman Born 1956. Ph.D. from Karolinska Institutet in Stockholm. Board member since 2016. Other appointments: Currently serves as Industry Executive at Avista Capital
2 nd Quarter Earnings Conference Call
2 nd Quarter Earnings Conference Call KKR & Co. Inc. Investor Update July 26, 2018 Recent Milestones K-1 $ Converted to a Corporation on July 1, 2018 Investor Day held on July 9, 2018 2 Key Metrics Assets
Faes Farma SA (FAE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Faes Farma SA (FAE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Faes Farma SA (FAE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business
NVESTOR. 1,400+ Attendees. 2,700+ Partnering Meetings. 768 Companies. 700 Registered Investors. 158 Company Presentations
February 11-12, 2019 New York Marriott Marquis Now in its 21 st year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and
Phoenix Semiconductor Philippines Corp (PSPC) to be listed on December 1, Semiconductor historical billings report in 000 US$
Report date: November 10, 2014 Phoenix Semiconductor Philippines Corp (PSPC) to be listed on December 1, 2014 Recommendation: Cautious buy with target price of Php 3.81/share At the final offer price of
Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile The Business
Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile
Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business
Aqua Pharmaceuticals, LLC
Aqua Pharmaceuticals, LLC Corporate Presentation June 2011 AQUA PHARMACEUTICALS, LLC 1 Company Overview Specialty dermatology pharmaceutical company currently focusing on acquiring, developing and marketing
2017 IPCC Attendee List
2017 IPCC Attendee List Includes attendees from both IPCC Spring and Fall 2017 Company Abbvie Inc. AbbVie Inc. AbbVie Inc. AgTech Accelerator AIPLA Akebia Therapeutics, Inc Alkermes, Inc. Alkermes, Inc.
35 YEARS OF ANALOG INNOVATION 35% NET PROFIT 121 QUARTERS OF POSITIVE CASH FLOW 30 YEARS ON THE NASDAQ 16 YEARS ON THE S&P ANNUAL REPORT
LINEAR TECHNOLOGY CORPORATION 2016 ANNUAL REPORT 16 YEARS ON THE S&P 500 121 QUARTERS OF POSITIVE CASH FLOW 30 YEARS ON THE NASDAQ 35% NET PROFIT 35 YEARS OF ANALOG INNOVATION Financial Highlights 35 Years
Bayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division
Bayer Inc. Science for a Better Life Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division Please review your career path to date, leading to your
Discovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D.
Discovery: From Concept to the Patient - The Business of Medical Discovery Todd Sherer, Ph.D. Associate Vice President for Research and Director of OTT President Elect, Association of University Technology
CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI WWW.CASIPHARMACEUTIALS.COM Forward Looking Statements This presentation contains forward-looking statements within
WORLD BANK GROUP SENIOR MANAGEMENT TEAM AND VICE PRESIDENTS. FINANCIAL DISCLOSURE FOR CALENDAR YEAR 2011 Summary for Public Disclosure
WORLD BANK GROUP SENIOR MANAGEMENT TEAM AND VICE PRESIDENTS FINANCIAL DISCLOSURE FOR CALENDAR YEAR 2011 Summary for Public Disclosure Name: Position/Title: WBG Organization: Madelyn Antoncic Vice President
4 th Quarter Earnings Conference Call
4 th Quarter Earnings Conference Call KKR & Co. L.P. Investor Update February 8, 2018 4Q17 Reflections Fundamentals Are Strong (Dollars in millions, except per unit amounts and unless otherwise stated)
UBS Pathfinders Trust, Treasury and Growth Stock Series 23
Dear Valued Client: This annual statement contains important information about your investment. The UBS Unit Trust thanks you for making this Pathfinders Trust a part of your financial plan. If you have
Biotech Concerto #6 Investment Process December 2008
Biotech Concerto #6 Investment Process December 2008 Index Biotech Investment Characteristics Investment Policy Investment Team Scientific Advisory Board Deal Flow Attrition Rate From Screening to Decision
Textron Reports Third Quarter 2014 Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1%
Textron Reports Third Quarter Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1% 10/17/ PROVIDENCE, R.I.--(BUSINESS WIRE)-- Textron Inc. (NYSE: TXT) today reported third
Investor Presentation & Financial Highlights. November 2018
Investor Presentation & Financial Highlights November 2018 Forward Looking Statements Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties.
North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio
MASTERCARD INC FORM 8-K. (Current report filing) Filed 09/11/08 for the Period Ending 09/09/08
MASTERCARD INC FORM 8-K (Current report filing) Filed 09/11/08 for the Period Ending 09/09/08 Address 2000 PURCHASE STREET PURCHASE, NY 10577 Telephone 9142492000 CIK 0001141391 Symbol MA SIC Code 7389
Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing
The 2010 EU industrial R&D investment SCOREBOARD
1 The 2010 EU industrial R&D investment SCOREBOARD Joint Research Centre European Commission Héctor Hernández 2 Contents 1. Background 2. Overall R&D trends 3. Top R&D companies 4. R&D by region 5. R&D
INDUSTRY REPORT for. Thomson Reuters Corporation
INDUSTRY REPORT for Thomson Reuters Corporation Overview of Thomson Reuters and Business Activities Thomson Reuters Corporation provides intelligent information for companies and individuals seeking competitive
LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
Life Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. New Jersey JLL Research
Life Sciences New Jersey 2017 An evolving industry: Today s clusters creating tomorrow s breakthroughs JLL Research 2 New Jersey Over the course of the past 130 years, the pharmaceutical/life sciences
Open Forum. Newton Glassman, Executive Chairman & CEO David Reese, President & COO. October 13, 2015
Open Forum Newton Glassman, Executive Chairman & CEO David Reese, President & COO October 13, 2015 Note: Callidus financials reflect most recent publicly released data (Q2 earnings, August 2015) 1 Welcome
TRENDS IN IP DISPUTES
ASSOCIATION OF CORPORATE COUNSEL LITIGATION COMMITTEE APRIL 25, 2017 TRENDS IN IP DISPUTES DAVID YURKERWICH MANAGING DIRECTOR IP PRACTICE LEADER 1 AGENDA Patent infringement and IPR filing trends Operating
Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5%
Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5% 07/16/2014 PROVIDENCE, R.I.--(BUSINESS WIRE)-- Textron Inc. (NYSE: TXT) today reported
Page 1 of 24 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C
Page 1 of 24 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE. INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13D-1(B) AND AMENDMENTS THERETO FILED PURSUANT TO 13D-2(B) SCHEDULE
Life Sciences CONFERENCE SERIES. Business Information in a Global Context LIFE SCIENCES IP PORTFOLIO. Business Development Pack
C5 Business Information in a Global Context Life Sciences CONFERENCE SERIES LIFE SCIENCES IP PORTFOLIO Business Development Pack C5 GROUPS LIFE SCIENCES EVENTS Pharmaceuticals, biotechnology, diagnostics,
BRUKER CORP FORM 8-K. (Current report filing) Filed 06/07/12 for the Period Ending 06/04/12
BRUKER CORP FORM 8-K (Current report filing) Filed 06/07/12 for the Period Ending 06/04/12 Address 40 MANNING RD BILLERICA, MA, 01821 Telephone 978663-3660 CIK 0001109354 Symbol BRKR SIC Code 3826 - Laboratory
Corporate Compliance & Transparency
4 th Annual Conference Corporate Compliance & Transparency in the Pharmaceutical Industry 24 25 February 2016 Zürich, Switzerland Conference In Numbers 84 Attendees 2 Days 29 Speakers 19 Participating
KOHLBERG CAPITAL CORPORATION. May 2007
KOHLBERG CAPITAL CORPORATION May 2007 Safe Harbor Statement Private Securities Litigation Reform Act of 1995 Forward Looking Information This presentation may include forward-looking statements. These
VITAL ENERGY INC. CORPORATE PRESENTATION
Suite 500, 940-6th Avenue S.W. Calgary, Alberta T2P 3T1 Tel: 403-699-9668 Fax:403-699-9660 Website: www.vitalenergyoil.com ITAL ENERGY INC. CORPORATE PRESENTATION June 2017 Safe Harbour Statement This
Pharmaceutical Co., Ltd. MEDICINE CNS/ENDOCRINOLOGY DEVELOPMENT LICENSING COMPANY PROFILE
WHANIN Pharmaceutical Co., Ltd. MEDICINE CNS/ENDOCRINOLOGY DEVELOPMENT LICENSING COMPANY PROFILE Board of Directors Chairman Vice Chairman President & CEO Vice President, Marketing Director (non-standing)
1Q 2016 Results. Mermaid Maritime Plc. May 23, 2016
Mermaid Maritime Plc 1Q 2016 Results May 23, 2016 Disclaimer: The information contained in this document is intended only for use during the presentation and should not be disseminated or distributed to
Teresa V. Pahl Partner
Teresa represents clients in all phases and aspects of their businesses. Teresa s expertise includes matters involving general corporate law, securities law and real property law. Teresa works with early-stage
Life Sciences Outlook
New Jersey 2018 JLL Research Report Life Sciences Outlook Breakthrough discoveries at a breathtaking pace 2 New Jersey The pharmaceutical/life sciences industry has historically been one of New Jersey
2Q 2016 Results. Mermaid Maritime Plc. August 2016
Mermaid Maritime Plc 2Q 2016 Results August 2016 Disclaimer: The information contained in this document is intended only for use during the presentation and should not be disseminated or distributed to
Booz & Company 30 October, Making Ideas Work. The 2012 Global Innovation 1000 Study
30 October, 2012 Making Ideas Work The 2012 Global Innovation 1000 Study Introduction R&D Spending Trends Analysis Front-End Innovation Survey Findings Summary 1 For the past eight years, has examined
Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2018
Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2018 0 0 Forward-looking Statements Strategies, plans, outlooks and other statements
Q4 & FY18 PERFORMANCE HIGHLIGHTS JUNE 2018
Q4 & FY18 PERFORMANCE HIGHLIGHTS JUNE 2018 Index Result Highlights 3 Operational Metrics 7 Financial Summary 10 New product offerings 14 Awards & Accolades 17 Annexure 19 Safe Harbour Statement The documents
Life Sciences Tools, Diagnostics, & Services Q Industry Overview
Life Sciences Tools, Diagnostics, & Services Q4 2017 Industry Overview Life Sciences Tools, Diagnostics, & Services: Industry Overview Key Takeaways M&A activity has remained steady at high volumes of
TRANSLATIONAL SCIENCE
TRANSLATIONAL SCIENCE A Discussion of Best Practices and Unique Models Wednesday January 31, 2018 at The NYSCF Research Institute HRA TRI-STATE REGIONAL MEETING 31 Wednesday January, 2018 AGENDA 8:30 AM
Overview of Venture Equity
Overview of Venture Equity SVB Analytics Report 2017 Written by SVB Analytics: Steve Liu Managing Director sliu@svb.com Sean Lawson Senior Manager slawson2@svb.com Steven Pipp Senior Associate spipp@svb.com
Confirms 2013 Financial Guidance
Confirms 2013 Financial Guidance PROVIDENCE, R.I.--(BUSINESS WIRE)--Jul. 17, 2013-- Textron Inc. (NYSE: TXT) today reported second quarter 2013 income from continuing operations of $0.40 per share, compared
We Work For Health Champions Awards Class of AstraZeneca: John McCarthy Vice President, Commercial Operations
We Work For Health Champions Awards Class of 2012 Brief Biographical Information (Alphabetical by Member Company) The We Work For Health Champion Awards are given annually to those to individuals who have
Speakers Bio: Jenny Tian Managing Director
Speakers Bio: Jenny Tian Managing Director Jenny has been in the investment management industry for most of her career which started in 1998. Prior to her current roles in the Springs Capital top management
IR Presentation. March 2014
IR Presentation March 2014 1 Table of Contents 1. 4Q13 Earnings Summary - Financial Highlights 2. Service & Business Strategy 3. Mobile 4. PC - Developing Quality Contents - Growth Strategy - Expanding
Investor Presentation. April 2015
Investor Presentation April 2015 KKR Global Leader in Alternative Asset Management Private Markets Public Markets Capital Markets Q1 2014 Q1 2015 2 Private Equity Energy $62 bn AUM $37 bn AUM $11.5 bn
Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio
Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio
Greater Yuma EDC Investors Making News
Greater Yuma EDC Investors Making News May 26, 2016 Issue RCFBH: Mobile Unit Local Seniors Awarded $5K In Scholarships From Alexander Ford Lincoln Johnson Controls Declared A Quarterly Dividend of $0.29
Dean A. Connor. President & Chief Executive Officer, Sun Life Financial
Dean A. Connor President & Chief Executive Officer, Sun Life Financial Dean A. Connor was appointed President & Chief Executive Officer, Sun Life Financial on December 1, 2011, and is a member of the company
PROTECT Project. Joanna Groves Chief Executive Officer 27 April 2010 EFPIA Patient Think-Tank Brussels, Belgium
PROTECT Project Joanna Groves Chief Executive Officer 27 April 2010 EFPIA Patient Think-Tank Brussels, Belgium Content of Presentation About IAPO Overview of PROTECT Work Package 4 - New methods for data
1 st Quarter Earnings Conference Call
1 st Quarter Earnings Conference Call KKR & Co. L.P. Investor Update April 27, 2017 1Q17 Reflections Key Business Themes Performance this quarter was strong as our model enabled us to capture more of everything
Scripps Networks Interactive Inc.
January 27, 2015 Scripps Networks Interactive Inc. (SNI-NYSE) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Outperform Date of Last Change 01/03/2011 Current Price (01/26/15) $73.49
WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview
Strategic Advisory Services 2018 Firm Overview Our Foundational Principles Strategic Advice for Biopharmaceutical, Medical Technology and Life Science sectors A Focus on Strategic Thinking in the Context
SAA s Structured Peer Group Analysis. STRATEGIC ASSET ALLIANCE, INC. Document not to be reproduced without the explicit consent of SAA.
SAA s Structured Peer Group Analysis Bonds Rated BBB*/Surplus This chart indicates your company s fixed income exposure to BBB rated bonds relative to your peers. Companies tend to increase BBB allocations